Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C

被引：21

作者：

Kumar, Sonal ^{[1
]}

Jacobson, Ira M. ^{[1
]}

机构：

[1] Weill Cornell Med Coll, Ctr Study Hepatitis C, Div Gastroenterol & Hepatol, New York, NY 10021 USA

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 61卷

关键词：

Hepatitis C; Sofosbuvir; Nucleoside/nucleotide polymerase inhibitors; SOFOSBUVIR PLUS RIBAVIRIN; TREATMENT-NAIVE PATIENTS; HCV GENOTYPE 1; TREATMENT-EXPERIENCED PATIENTS; FIXED-DOSE COMBINATION; INTERFERON-FREE; DOUBLE-BLIND; OPEN-LABEL; INFECTION; VIRUS;

D O I：

10.1016/j.jhep.2014.09.006

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The treatment of hepatitis C virus (HCV) has made significant advances with the development of new direct-acting antivirals. Nucleotide polymerase inhibitors are one class of these new medications that have been shown to be highly effective, safe and well tolerated as part of an antiviral regimen. Sofosbuvir has become the first drug in this class to be approved for clinical use, supported by results from extensive phase II and phase III clinical trials. This review will further discuss nucleotide polymerase inhibitors, including the data supporting their use as part of interferon-free HCV treatment regimens. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

页码：S91 / S97

页数：7

共 49 条

[1] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[2] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Reddy, K. Rajender ;

Nelson, David R. ;

Lawitz, Eric ;

Gordon, Stuart C. ;

Schiff, Eugene ;

Nahass, Ronald ;

Ghalib, Reem ;

Gitlin, Norman ;

Herring, Robert ;

Lalezari, Jacob ;

Younes, Ziad H. ;

Pockros, Paul J. ;

Di Bisceglie, Adrian M. ;

Arora, Sanjeev ;

Subramanian, G. Mani ;

Zhu, Yanni ;

Dvory-Sobol, Hadas ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

Kwo, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493

[3]

Afdhal NH, 2004, SEMIN LIVER DIS

[4]

Curry MP, 2013, HEPATOLOGY, V58, p314A

[5] SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY [J].

Esteban, R. ;

Nyberg, L. ;

Lalezari, J. ;

Ni, L. ;

Doehle, B. ;

Kanwar, B. ;

Brainard, D. ;

Subramanian, M. ;

Symonds, W. T. ;

McHutchison, G. ;

Rodriquez-Torres, M. ;

Zeuzem, S. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S4-S5

[6] SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION [J].

Everson, G. T. ;

Tran, T. T. ;

Towner, W. J. ;

Davis, M. N. ;

Wyles, D. ;

Nahass, R. ;

McNally, J. ;

Brainard, D. M. ;

Han, L. ;

Doehle, B. ;

Mogalian, E. ;

Symonds, W. T. ;

McHutchison, J. G. ;

Morgan, T. ;

Chung, R. T. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S46-S46

[7] Interferon-Free Strategies with a Nucleoside/Nucleotide Analogue [J].

Feld, Jordan J. .

SEMINARS IN LIVER DISEASE, 2014, 34 (01) :37-46

[8] Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C [J].

Fontana, R. J. ;

Hughes, E. A. ;

Bifano, M. ;

Appelman, H. ;

Dimitrova, D. ;

Hindes, R. ;

Symonds, W. T. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (06) :1601-1605

[9] SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE [J].

Gane, E. J. ;

Hyland, R. H. ;

An, D. ;

Pang, P. S. ;

Symonds, W. T. ;

Mchutchison, J. G. ;

Stedman, C. A. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S3-S4

[10] ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY [J].

Gane, E. J. ;

Stedman, C. A. ;

Hyland, R. H. ;

Pang, P. S. ;

Ding, X. ;

Symonds, W. T. ;

McHutchison, J. G. .

JOURNAL OF HEPATOLOGY, 2013, 58 :S6-S7

← 1 2 3 4 5 →